PROLOR Biotech, (FRA:M3D) Other Current Receivables : €0.15 Mil (As of Mar. 2013)

View and export this data going back to . Start your Free Trial

What is PROLOR Biotech, Other Current Receivables?

PROLOR Biotech,'s Other Current Receivables for the quarter that ended in Mar. 2013 was €0.15 Mil.

PROLOR Biotech,'s quarterly Other Current Receivables increased from Sep. 2012 (€0.13 Mil) to Dec. 2012 (€0.30 Mil) but then stayed the same from Dec. 2012 (€0.30 Mil) to Mar. 2013 (€0.15 Mil).

PROLOR Biotech,'s annual Other Current Receivables declined from Dec. 2010 (€0.49 Mil) to Dec. 2011 (€0.25 Mil) but then increased from Dec. 2011 (€0.25 Mil) to Dec. 2012 (€0.30 Mil).

PROLOR Biotech, Other Current Receivables Historical Data

The historical data trend for PROLOR Biotech,'s Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROLOR Biotech, Other Current Receivables Chart

PROLOR Biotech, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Other Current Receivables

Get a 7-Day Free Trial

0.26

0.03

0.49

0.25

0.30

PROLOR Biotech, Quarterly Data
	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13
Other Current Receivables	Get a 7-Day Free Trial															0.29	0.39	0.13	0.30	0.15

PROLOR Biotech, Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

PROLOR Biotech, Other Current Receivables Related Terms

Thank you for viewing the detailed overview of PROLOR Biotech,'s Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

PROLOR Biotech, Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PROLOR Biotech, Inc. (FRA:M3D) » Definitions » Other Current Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

PROLOR Biotech, Inc., formerly known as Modigene Inc., was formed on August 22, 2003 under the laws of the state of Nevada under the name LDG, Inc. It was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. The Company develops proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company's products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development also comprise anti-obesity peptide oxyntomodulin, factor VIIa, interferon ÃŸ and erythropoietin, and atherosclerosis and rheumatoid arthritis long-acting therapies.

PROLOR Biotech, Headlines

No Headlines